Sophia Genetics and Karkinos Healthcare have forged a strategic partnership to broaden access to genomic testing and research, with a shared goal of enhancing health outcomes through precision oncology.

The collaboration aims to empower healthcare institutions with tools for data-driven medicine, particularly focusing on cancer testing in various regions.

Karkinos Healthcare will leverage SOPHiA GENETICS' advanced technology to analyze blood cancers and solid tumors. The platform, known for streamlining workflows and accelerating analysis, will contribute to more efficient and precise diagnostics.

The collaboration's primary focus is on identifying the genomic landscape for the Indian population, with an overarching goal to advance precision medicine. The partnership seeks to generate valuable evidence that can contribute to improved cancer control and management strategies.

Dr. Jurgi Camblong, CEO of SOPHiA GENETICS, expressed the ambition to expand access to precision oncology and provide local health institutions with the necessary tools for data-driven medicine.

Dr. R Venkataramanan, CEO of Karkinos Healthcare, highlighted the alliance's potential to drive evidence-based research, enabling faster diagnosis and enhanced cancer management, particularly benefiting diverse communities. The partnership signifies a significant step toward advancing genomic testing capabilities and fostering impactful research in the field of oncology.